Voyager Therapeutics — Biomedical Watch V2

Traitements7programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

7

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Anti-AAV9 Total Antibody (TAb) AssayVY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study	Alzheimer	Phase 1	À vérifier	United States	À vérifier
VY1706 High DoseVY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study	Alzheimer	Phase 1	À vérifier	United States	À vérifier
VY1706 Low doseVY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study	Alzheimer	Phase 1	À vérifier	United States	À vérifier
VY1706 Mid doseVY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study	Alzheimer	Phase 1	À vérifier	United States	À vérifier
VY7523This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.	Alzheimer	Phase 1/2	À vérifier	United States, Canada	À vérifier
VY1706 Low doseVY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study	Alzheimer	Phase 1	À vérifier	United States	À vérifier
VY7523This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.	Alzheimer	Phase 1/2	À vérifier	United States, Canada	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
VY7523	Alzheimer	Phase 1/2	NCT06874621	VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease	ACTIVE_NOT_RECRUITING
VY1706 Low dose	Alzheimer	Phase 1	NCT07764146	An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.